UCC December 2021

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

"The explosion in the number of therapies in this particular disease segment, especially those that have been deemed BCG unresponsive, seems very reminiscent to that witnessed in the mCRPC space a decade ago," writes Raoul S. Concepcion, MD, FACS.

Benefits include improved quality of life and symptom management.

Multiple investigational agents have been developed and are being studied.

Growing evidence supports the existence of an intermediate metastatic disease state.